Randomized phase II/III study of R-CHOP versus weekly rituximab plus CHOP for CD20 positive diffuse large B cell lymphoma (JCOG0601)
Latest Information Update: 19 Jan 2024
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 12 Dec 2023 Results assessing long-term efficacy and safety of the JCOG 0601 trial after 8 years follow-up from the end of accrual, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 12 Dec 2023 Results of Supplementary Analysis (n=401) assessing The Prognostic Impact of Relative Dose Intensity of Vincristine in R-CHOP for Untreated Patients with Diffuse Large B-Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 04 Dec 2018 Status changed to completed as per results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology